Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Operating Expenses: 2024-2025

Historic Other Operating Expenses for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to -$8.6 million.

  • Monte Rosa Therapeutics' Other Operating Expenses fell 15.01% to -$8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.1 million, marking a year-over-year change of. This contributed to the annual value of -$29.6 million for FY2024, which is 123562.50% down from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Other Operating Expenses stood at -$8.6 million, which was down 9.22% from -$7.8 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Other Operating Expenses high stood at $59,000 for Q1 2025, and its period low was -$8.6 million during Q3 2025.
  • Its 2-year average for Other Operating Expenses is -$6.6 million, with a median of -$7.6 million in 2024.
  • Examining YoY changes over the last 5 years, Monte Rosa Therapeutics' Other Operating Expenses showed a top increase of 100.87% in 2025 and a maximum decrease of 15.01% in 2025.
  • Monte Rosa Therapeutics' Other Operating Expenses (Quarterly) stood at -$7.7 million in 2024, then declined by 15.01% to -$8.6 million in 2025.
  • Its Other Operating Expenses was -$8.6 million in Q3 2025, compared to -$7.8 million in Q2 2025 and $59,000 in Q1 2025.